Previous Close | 127.90 |
Open | 128.60 |
Bid | 130.10 x 1500 |
Ask | 130.20 x 8800 |
Day's Range | 128.50 - 130.70 |
52 Week Range | 79.70 - 130.70 |
Volume | 61,890 |
Avg. Volume | 152,014 |
Market Cap | 4.1B |
Beta (5Y Monthly) | 1.17 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.04 |
Earnings Date | Oct 29, 2019 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 107.55 |
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 12, 2019 / MorphoSys (NASDAQ:MOR) (FSE:MOR): Dear Madam/Sir, Please note MorphoSys's financial reporting dates 2020 as follows: For a direct import of the ...
Morphosys' chief scientific officer will quit after 17 years with the group, the latest change at the top of the German biotech firm as it gears up for its first product launch. The group said late on Wednesday that CSO Markus Enzelberger would step down at the end of February to explore new opportunities. The shares dropped 2.1% at 0853 GMT on Thursday as one trader pointed to Enzelberger's "crucial position" at Morphosys.
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 20, 2019 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announced that Dr. Markus Enzelberger, the company's Chief Scientific Officer (CSO), has decided to step down as CSO and member of the company's Management Board to explore new opportunities. Dr. Enzelberger will leave MorphoSys on February 29, 2020.
IDMC recommends to increase patient number from currently 330 to 450. MARTINSRIED, GERMANY / ACCESSWIRE / November 18, 2019 / MorphoSys (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) today announced that the ongoing tafasitamab phase 3 B-MIND study has successfully passed the pre-planned, event-driven interim analysis for futility. An independent data monitoring committee (IDMC) reviewed the data and recommended to increase the number of patients from currently 330 to 450.
PLANEGG/MUNICH, GERMANY and BOSTON MA / ACCESSWIRE / November 15, 2019 / MorphoSys (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today the opening of its new U.S. headoffice. ...
MorphoSys AG (ETR:MOR) shareholders might be concerned after seeing the share price drop 10% in the last quarter. But...
Q3 2019 Morphosys AG Earnings Call
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 11, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Novartis presented phase 2 results ...
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 6, 2019 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) today announced presentation of so far unpublished data on tafasitamab, ...
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 29, 2019 / MorphoSys AG Reports Third Quarter 2019 Financial Results Conference call and webcast (in English) to be held on October 30, 2019 at 2:00pm CET ...
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 29, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) today announced topline results from the primary analysis of the retrospective ...
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 29, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR): Primary endpoint met: Statistically significant superior best objective ...
NASDAQ:MOR) today announced the end of the clinical development program of MOR106 in atopic dermatitis. The joint decision of all three involved parties, Galapagos NV, MorphoSys AG and Novartis Pharma AG, was based on an interim analysis for futility that was performed in the Phase 2 IGUANA trial. The clinical development program of MOR106 in atopic dermatitis included the two Phase 2 studies IGUANA and GECKO, as well as a Phase 1 bridging study for subcutaneous formulation and a Japanese ethno-bridging study.
NASDAQ: MOR) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the end of the clinical development program of MOR106 in atopic dermatitis. The joint decision of all three involved parties, Galapagos NV, MorphoSys AG and Novartis Pharma AG, was based on an interim analysis for futility that was performed in the Phase 2 IGUANA trial. The clinical development program of MOR106 in atopic dermatitis included the two Phase 2 studies IGUANA and GECKO, as well as a Phase 1 bridging study for subcutaneous formulation and a Japanese ethno-bridging study.
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the first […]
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 21, 2019 / MorphoSys AG (FSE:MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ:MOR) will publish its first nine months' 2019 results on October 29, 2019 ...
Half Year 2019 Morphosys AG Earnings Call
NASDAQ:MOR) and I-Mab Biopharma (I-Mab) announced today that I-Mab has received Investigational New Drug (IND) clearances from the National Medical Products Administration (NMPA) of China to expand the ongoing phase 2 and 3 clinical trials of MOR202/TJ202, MorphoSys's human monoclonal anti-CD38 antibody for the treatment of multiple myeloma (MM), also to mainland China.
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / September 18, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) will present at the following conferences: Baader Investment Conference ...
MorphoSys's Licensee Janssen Submits Biologics License Application to U.S. FDA of Tremfya (R) (Guselkumab) for Treatment of Adults with Active Psoriatic Arthritis PLANEGG / MUNICH, GERMANY / ACCESSWIRE ...
MOR earnings call for the period ending June 30, 2019.
B-MIND compares the efficacy of tafasitamab (MOR208) plus bendamustine versus rituximab plus bendamustine in patients with relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL). The biomarker, which is the basis for a co-primary endpoint, is described as a low baseline peripheral blood natural killer (NK) cell count and was implemented in agreement with the FDA as an amendment of B-MIND in the first quarter of this year. Patients with a low number of NK cells (defined as 100 or fewer NK cells per microliter blood) at study entry represent approximately 50% of the overall study population and are believed to exhibit a less favorable response to anti-CD20-based therapies.
MUNICH, GERMANY / ACCESSWIRE / August 6, 2019 / MorphoSys AG Reports Second Quarter 2019 Financial Results Conference call and webcast (in English) to be held on August 7, 2019 at 2:00pm CEST (1:00pm BST/8:00am ...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / August 6, 2019 / MorphoSys AG (FSE:MOR) (Prime Standard Segment:MDAX) (Prime Standard Segment:TecDAX) (NASDAQ:MOR) today announced its intention to submit a Marketing ...
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 25, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; Nasdaq: MOR) will publish its first six months' 2019 results on August 6, 2019 at 10:00pm ...